lercanidipine has been researched along with dihydropyridines in 229 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (5.24) | 18.2507 |
| 2000's | 103 (44.98) | 29.6817 |
| 2010's | 101 (44.10) | 24.3611 |
| 2020's | 13 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, G; Greto, L; Leonardi, A; Montagna, E; Sironi, G; Testa, R | 1 |
| Angelico, P; Guarneri, L; Ibba, M; Leonardi, A; Poggesi, E; Taddei, C; Testa, R | 1 |
| Greto, L; Leonardi, A; Montagna, E; Sironi, G; Testa, R | 1 |
| Accomazzo, MR; Bonfatti, M; Corsini, A; Fumagalli, R; Nicosia, S; Paoletti, R; Quarato, P; Raiteri, M; Sartani, A; Testa, R | 1 |
| van Zwieten, PA | 1 |
| Herbette, LG; Leonardi, A; Sartani, A; Vecchiarelli, M | 1 |
| Accomazzo, MR; Bernini, F; Canavesi, M; Catapano, AL; Corsini, A; Fumagalli, R; Paoletti, R; Sartani, A; Testa, R | 1 |
| Mancia, G; Omboni, S; Zanchetti, A | 1 |
| Omboni, S; Zanchetti, A | 1 |
| Baetta, R; Barberi, L; Catapano, AL; Comparato, C; Donetti, E; Farina, P; Leonardi, A; Natali, M; Soma, MR | 1 |
| Angelico, P; Guarneri, L; Leonardi, A; Testa, R | 1 |
| Krzesinski, JM | 1 |
| Amenta, F; Leonardi, A; Sabbatini, M; Testa, R; Vitaioli, L | 1 |
| Amenta, F; Baldoni, E; Sabbatini, M; Vitaioli, L | 1 |
| Belcaro, G; Bucci, M; Cesarone, MR; Ciccarelli, R; De Sanctis, MT; Incandela, L; Ledda, A; Pellegrini, L; Steigerwalt, R | 1 |
| Cerbai, E; Davoli, G; DePaoli, P; DiCiolla, F; Lisi, G; Maccherini, M; Matucci, R; Mugelli, A; Sani, G; Sartiani, L | 1 |
| Bellosta, S; Bernini, F | 1 |
| Barbagallo Sangiorgi, G; Barbagallo, M | 1 |
| Jarvis, B; McClellan, KJ | 1 |
| Amenta, F; Sabbatini, M; Tomassoni, D | 2 |
| Cleophas, TJ; van der Meulen, J; van Ouwerkerk, BM; Zwinderman, AH | 1 |
| Barsotti, A; Belcaro, G; Bucci, M; Cacchio, M; Cesarone, MR; Cornelli, U; De Sanctis, MT; Di Renzo, A; Griffin, M; Incandela, L; Martines, G; Nicolaides, AN | 1 |
| Bolego, C; Cignarella, A; Pinna, C; Puglisi, L; Zanardo, R | 1 |
| Amenta, F; Leonardi, A; Sabbatini, M; Testa, R; Tomassoni, D; Vitaioli, L | 1 |
| Ram, CV | 2 |
| Klotz, U | 1 |
| Barrios, V; Carrasco, JL; Esteras, A; Herranz, I; Luque, M; Navarro, A; Navarro-Cid, J; Prieto, L; Romero, J; Ruilope, LM; Tamargo, J | 1 |
| Viviani, GL | 1 |
| Davies, P; James, IG; Jones, A | 1 |
| Levi, Z; Rachmani, R; Ravid, M; Zadok, BS | 1 |
| Leonetti, G; Magnani, B; Pessina, AC; Rappelli, A; Trimarco, B; Zanchetti, A | 1 |
| Alvarez-Lueje, A; Núñez-Vergara, LJ; Pujol, S; Squella, JA | 1 |
| Dumont, L; Leonardi, A; Massicotte, J; Sironi, G; Viens, A; Wang, H; Yao, MH | 1 |
| Zanchetti, A | 2 |
| Bolla, G; Grassi, G; Mancia, G; Seravalle, G; Turri, C | 1 |
| Ghiadoni, L; Magagna, A; Salvetti, A; Salvetti, G; Taddei, S; Versari, D; Virdis, A | 1 |
| Campagnola, M; Cominacini, L; Davoli, A; Fratta Pasini, A; Garbin, U; Lo Cascio, V; Nava, C; Pastorino, AM; Rossato, P | 1 |
| Helberg, S; Istad, H; Lund-Johansen, P; Madsbu, S; Risberg, K; Rønnevik, PK; Stranden, E; Wessel-Aas, T | 1 |
| Amenta, F; Peleg, E; Rosenthal, T; Sabbatini, M; Tomassoni, D | 1 |
| Ambrosioni, E; Borghi, C; Dormi, A; Prandin, MG | 1 |
| Aguilar, A; Angulo, E; Canelada, JA; Cidoncha, F; Díaz Olea, E; Fuentes, J; Garrido, J; Guerras, M; Hidalgo, P; Iglesias, M; Lapie, J; López Acedo, A; Peña, J; Robles, NR | 1 |
| Abellán Alemán, J; Fernández Montero, F; Gil Guillén, V; Latorre Hernández, J; Martínez García, JF; Merino Sánchez, J; Navarro Lima, A | 1 |
| Corradi, L; Derosa, G; Fogari, R; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Benzie, IF; Tomlinson, B | 1 |
| Balbarini, A; Dell'Omo, G; Mariani, M; Menegato, A; Nuti, M; Pedrinelli, R | 1 |
| Greenough, A; McDonald, C; Millar-Craig, M; Mitchell, L; Shaffu, B | 1 |
| Bonato, PS; Coelho, EB; dos Santos, NA; Ifa, DR; Jabor, VA; Lanchote, VL | 1 |
| Ceriotti, F; Fedele, D; Lapolla, A; Mosca, A; Paleari, R | 1 |
| Bang, LM; Chapman, TM; Goa, KL | 1 |
| Erk, N | 1 |
| Al Tamimi, JI; Farina, P; Idrees, J; Salem, II | 1 |
| Herzig, S; Wirtz, S | 1 |
| Bassous, M; Clerson, P; Goullard, L; Grès, CS; Poncelet, P; Ribstein, J | 1 |
| Baldini, N; Bellosta, S; Bernini, F; Canavesi, M; Leonardi, A; Sironi, G | 1 |
| Calls, J; Gómez Campderá, F; Herrera, J; Liébana, A; Manjón, M; Marco, J; Martínez Fernández, J; Méndez, ML; Morey, A; Ocón, J; Pastor, L; Rincón, B; Robles, NR; Rodríguez Martínez, MA; Rodríguez Villareal, I; Tornero, F; Torrijos, J; Villatoro, J | 1 |
| Coelho, EB; Jabor, VA; Lanchote, VL | 1 |
| Christensen, KL | 1 |
| Calls, J; Gomez, CF; Herrera, J; Liebana, A; Manjon, M; Marco, J; Martinez, FI; Mendez, ML; Morey, A; Ocon, J; Pastor, L; Rincon, B; Robles, NR; Rodriguez, MM; Rodríguez, VI; Tornero, F; Torrijos, J; Villatoro, J | 1 |
| Kaul, C; Ramarao, P; Sonkusare, S; Srinivasan, K | 1 |
| Aburada, M; Kase, Y; Maruyama, H; Sasaki, T; Takeda, S | 1 |
| Aissi, K; Bagneres, D; Bonin-Guillaume, S; Coutant, G; Demoux, AL; Frances, Y; Grandel, B; Rossi, P | 1 |
| Brixius, K; Geissler, HJ; Gross, T; Hekmat, K; Mehlhorn, U; Schwinger, RH; Tossios, P | 1 |
| Campo, C; Parati, G; Roldán, C; Ruilope, LM; Saavedra, J; Segura, J | 1 |
| Crepaldi, G; Dalla Vestra, M; Fioretto, P; Grazioli, V; Lapolla, A; Mosca, A; Pozza, G | 1 |
| Agrawal, R; Haller, H; Marx, A | 1 |
| Bertucci, C; Cavrini, V; Fiori, J; Gotti, R | 1 |
| Coelho, EB; Gerlach, RF; Lopes, LF; Martinez, ML; Nobre, F; Rocha, JB; Tanus-Santos, JE | 1 |
| Agrawal, R; Bahlmann, FH; Bode-Böger, SM; Fliser, D; Haller, H; Kielstein, JT; Kirsch, T; Lindschau, C; Marx, A; Meier, M; Menne, J; Muller, D; Park, JK | 1 |
| Huang, CH; Lai, WT; Lin, TH; Sheu, SH; Su, HM; Voon, WC; Yen, HW | 1 |
| Dogan, E; Erkoc, R; Sayarlioglu, H; Soyoral, Y; Topal, C | 1 |
| Borghi, C | 2 |
| Kalovidouris, M; Koutsopoulou, M; Michalea, S; Panderi, I; Robola, N | 1 |
| Burnier, M; Pechère, A; Waeber, B | 1 |
| Burnier, M; Meier, P | 1 |
| Barrios, L; Barrios, V; Calderón, A; Escobar, C; Navarro, A; Navarro-Cid, J | 1 |
| Hair, PI; Perry, CM; Scott, LJ | 1 |
| Farah, R; Klempef, R; Kristal, B; Sela, S; Shapiro, G; Shurtz-Swirski, R; Snitkovski, T | 1 |
| Bueno-Gómez, J; Camacho-Azcargorta, I; Mora-Maciá, J; Navarro, A; Roma, J; Tisaire-Sánchez, J | 1 |
| Beckey, C; Lundy, A; Lutfi, N | 1 |
| Cuspidi, C; Grassi, G; Mancia, G; Quarti-Trevano, F; Scopelliti, F; Seravalle, G | 1 |
| Amenta, F; Rosenmann, E; Rosenthal, T; Tomassoni, D | 1 |
| Calvo, C; Ghezzi, C; Luurila, H; Luurila, O; Puig, JG; Strandberg, A; Sulosaari, S | 1 |
| Burnier, M; Gasser, UE | 1 |
| Borghi, C; Cicero, AF; Cosentino, E; Dormi, A; Prandin, MG; Strocchi, E; Veronesi, M | 1 |
| Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J | 2 |
| Charde, S; Kumar, L; Mudgal, M; Saha, R | 1 |
| Haller, H; Menne, J | 1 |
| Bendhack, LM; Castro, MM; Demacq, C; Fernandes, K; Gerlach, RF; Martinez, ML; Rizzi, E; Tanus-Santos, JE | 1 |
| Farah, R; Shurtz-Swirski, R | 1 |
| Bendhack, LM; Castro, MM; Fernandes, K; Gerlach, RF; Martinez, ML; Rizzi, E; Tanus-Santos, JE | 1 |
| Chai, CY; Chen, IJ; Dai, ZK; Liang, JC; Lin, SW; Liou, SF; Wu, JR; Yeh, JL | 1 |
| Boralli, VB; Coelho, EB; Lanchote, VL; Marques, MP; Sampaio, SA | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Chin, D; Ferrucci, A; Pagannone, E; Palano, F; Tocci, G; Volpe, M | 1 |
| Chen, WL; Tsao, YT | 1 |
| Burnier, M; Maillard, MP; Pruijm, MT | 1 |
| Brown, MJ; Cockcroft, JR; Dhakam, Z; Mackenzie, IS; McEniery, CM; Wilkinson, IB | 1 |
| Chia, YC; Chua, CT; Khoo, EM; Ng, CJ; Yeoh, ES | 1 |
| Chatzikyrkou, C; Haller, H; Menne, J | 1 |
| Burnier, M; Pruijm, M; Wuerzner, G | 1 |
| Ferrari, P; Glover-Koudounas, S; Makarounas-Kirchmann, K | 1 |
| Pandit, SS; Patil, AT | 1 |
| Beyenik, H; Dogan, E; Erkoc, R; Sayarlioglu, H; Topal, C | 1 |
| Cubero, JJ; de Vinuesa, EG; Robles, NR; Romero, B; Sánchez-Casado, E | 1 |
| Li, CJ; Shi, ZD | 1 |
| Bianchetti, MG; Fossali, EF; Milani, G; Ragazzi, M; Ramelli, GP; Rizzi, M; Simonetti, GD | 1 |
| Bastos, MF; Brilhante, FV; Duarte, PM; Gonçalves, TE; Marques, MR; Napimoga, MH; Pires, AG | 1 |
| Rump, LC | 1 |
| Garweg, C; Lancellotti, P; Mélon, P; Piérard, L | 1 |
| Gumustas, M; Ozkan, SA; Sanli, N; Sanlı, S | 1 |
| Chu, P; Hsiao, PJ; Lin, HW; Lin, SH; Sung, CC; Wang, CW | 1 |
| Borghi, C; Cicero, AF | 1 |
| Kim, IS; Kim, Y; Lee, JJ; Lee, KH; Myung, CS; Park, HJ; Shin, CY; Zhang, WY | 1 |
| Hadjipavlou, G; Hafeez, A; Hughes, T; Messer, B | 1 |
| Harada, N; Niwa, M; Sakurai-Yamashita, Y | 1 |
| Sansanayudh, N; Veerayuthvilai, S; Wongwiwatthananukit, S | 1 |
| Schattner, A | 1 |
| Amin, S; Kohli, K; Parmar, N; Singla, N | 1 |
| Borghi, C; Cicero, AF; Gerocarni, B; Rosticci, M | 1 |
| Bramlage, P; Kreutz, R; Scholze, J; Trenkwalder, P | 1 |
| Ramakrishna, K; Sastry, TM | 1 |
| Álvarez, C; Frías, J; García-Arieta, A; Gómez, E; Govantes, C; Guerra, P; Simón, M | 1 |
| Huang, J; Luo, M; Shen, Y; Xu, H; Zheng, H | 1 |
| Chen, K; Guo, R; Liu, S; Liu, X; Teng, Y; Wang, B; Wei, C; Yuan, G; Zhang, D; Zhang, J; Zhang, R; Zhao, W | 1 |
| Jirwankar, P; Mehta, S; Pandey, S; Pandit, S; Patil, A; Tripathi, P | 1 |
| Fomin, VV; Svistunov, AA | 1 |
| Iosava, IK; Minushkina, LO | 1 |
| Bastos, MF; Dias Gonçalves, TE; Duarte, PM; Marques, MR; Napimoga, MH; Pires, AG; Vasconcelos de Araújo, I; Vilhena Brilhante, F | 1 |
| Chen, IJ; Hsu, JH; Liang, JC; Liou, SF; Yeh, JL | 1 |
| Avadhani, K; Deshpande, PB; Kulkarni, RV; Menon, J; Mutalik, S; Shetty, PK; Suthar, NA | 1 |
| Farah, R; Khamisy-Farah, R; Shurtz-Swirski, R | 1 |
| Afanas'ev, SA; Kondrat'eva, DS; Kozlov, BN; Mordovin, VF; Ripp, TM; Suslova, TE | 1 |
| An, WS; Chen, GH; Chen, T; Li, JD; Yang, TS; Zhang, XX; Zhong, ZY | 1 |
| Elhebir, ES; Hilmi, SC; Hughes, JD | 1 |
| Striuk, RI | 1 |
| Maksimov, ML; Malykhina, AI | 1 |
| Burnier, M | 1 |
| Cao, Z; Chen, L; Su, C; Tao, J; Wang, Y; Xia, WH; Xie, WL; Xu, SY; Yu, BB; Zhang, B; Zhang, XY | 1 |
| Caimi, L; Cancarini, A; De Ciuceis, C; Duse, S; La Boria, E; Muiesan, ML; Paini, A; Ricotta, D; Rizzoni, D; Rosei, CA; Rosei, EA; Rossini, C; Ruggeri, G; Salvetti, M; Sarkar, A; Semeraro, F | 1 |
| Ahmad, N; Amin, S; Kohli, K; Neupane, YR | 1 |
| Ghodake, VN; Korabu, SS; Ranpise, NS | 1 |
| Gao, Y; Wang, G; Zhao, F | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 2 |
| Agabiti Rosei, E; De Ciuceis, C; Di Gregorio, J; Donini, C; Flati, V; La Boria, E; Pasini, E; Petroboni, B; Porteri, E; Rizzoni, D; Rossini, C; Rufo, A | 1 |
| Brown, I; Gallivan, C | 1 |
| Minushkina, LO | 1 |
| Maldonado, J; Pereira, T; Tavares, A | 1 |
| Ausheva, AK; Karpova, AV; Pogosova, GV; Salbieva, AO | 1 |
| Chazova, I; Coca, A; Girerd, X; Haller, H; Mancia, G; Pauletto, P; Pupek-Musialik, D; Svyshchenko, Y | 1 |
| Özcan, EE; Özel, E; Öztürk, A; Senaslan, Ö; Uyar, S | 1 |
| Baek, IH; Cho, W; Choo, GH; Ha, ES; Hwang, SJ; Jin, SE; Jung, YS; Kim, JS; Kim, MS | 1 |
| Kohl-Himmelseher, M; Kuballa, T; Lachenmeier, DW; Monakhova, YB | 1 |
| Beato-Coo, L; Blanco-García, R; Fernández-Fleming, F; Martín-Báez, I; Moreiras-Plaza, M | 1 |
| Javeri, Y; Juneja, D; Nasa, P; Singh, A; Singh, O | 1 |
| Dumitriu, AS; Gheorghiu, IM; Mironiuc-Cureu, M; Stoian, IM | 1 |
| Yang, Z | 1 |
| Arnaout, S | 1 |
| Dong, H; Jiang, XJ; Peng, M; Wu, HY; Yang, Y; Zhang, HM; Zou, YB | 1 |
| Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S | 2 |
| Cao, TS; Huynh, VM; Tran, VH | 1 |
| Angeloni, E; Lombardo, P; Pirelli, M; Refice, S; Vitaterna, A | 1 |
| Deshpande, PB; Mutalik, S; Nayak, UY; Reddy, GS | 1 |
| Dolidze, NM; Gezeli, TD; Tabidze, GA; Tsibadze, TA | 1 |
| Bruno, RM; Cartoni, G; Ferri, C; Ghiadoni, L; Grassi, D; Magagna, A; Stea, F; Taddei, S; Virdis, A | 1 |
| Ahn, JC; Ahn, T; Cha, DH; Cho, JH; Cho, SW; Choi, DJ; Hong Baek, S; Hong, S; Hong, TJ; Jeon, ES; Jeon, HK; Jeong, JO; Jeong, MH; John, SH; Juhn, JH; Kang, JH; Kim, BS; Kim, DW; Kim, JJ; Kim, MH; Kim, NH; Kim, SK; Kim, SW; Kim, SY; Kim, YN; Kwan, J; Lee, HY; Lee, NH; Lee, SH; Lee, SY; Lee, YJ; Na, SH; Oh, BH; Park, CG; Park, SH; Park, WJ; Rhee, MY; Ryu, JK; Shin, ES; Shin, JH; Uk Lee, S; Won, KH; Yoo, SY | 1 |
| Gosteva, EV; Vasil'eva, LV | 1 |
| D'Angelo, A; Derosa, G; Franzetti, I; Maffioli, P; Mugellini, A; Pesce, RM; Querci, F | 1 |
| Avram, S; Borcan, F; Borcan, LC; Duda-Seiman, C; Duda-Seiman, D; Mancas, S | 1 |
| Chazova, I; Coca, A; Girerd, X; Haller, H; Mancia, G; Omboni, S; Parati, G; Pauletto, P; Pupek-Musialik, D; Svyshchenko, Y | 1 |
| Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B | 1 |
| Bombelli, M; Brambilla, G; Casati, A; Cuspidi, C; Grassi, G; Mancia, G; Pizzalla, DP; Riva, M; Seravalle, G | 1 |
| Bisenieks, E; Duburs, G; Gall Troselj, K; Krauze, A; Poikans, J; Velena, A; Zarkovic, N | 1 |
| Chonkar, AD; Dengale, S; Jain, P; Managuli, RS; Mutalik, S; Rao, JV; Udupa, N | 1 |
| D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM | 1 |
| Agabiti-Rosei, C; Agabiti-Rosei, E; Airò, P; Caimi, L; De Ciuceis, C; Ricotta, D; Rizzoni, D; Rossini, C; Ruggeri, G; Scarsi, M; Tincani, A | 1 |
| Ding, L; He, X; Jian, L; Li, X; Shi, F | 1 |
| Arumugam, K; Averineni, RK; Deshpande, A; Deshpande, PB; Gurram, AK; Musmade, P; Mutalik, S; Reddy, MS; Shavi, GV; Udupa, N | 1 |
| Haiya, W; Ningyuan, F; Peixiao, S | 1 |
| Rizzoni, D | 2 |
| Parati, G | 1 |
| Calvo, C; Espinel, E; Esteban, R; Macias, JF; Mateos, L; Robles, NR; Sobrino, J | 1 |
| Dimitriadis, K; Mani, I; Mantzouranis, E; Tousoulis, D; Tsioufis, C; Tsioufis, K | 1 |
| Gupta, S; Gupta, YK; Jagannathan, NR; Sharma, U | 2 |
| Antza, C; Kotsis, V; Stabouli, S | 1 |
| de Vries, C; Haerden, Y; Lins, R | 1 |
| Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH | 1 |
| Alegre, F; Basualdo, JE; Fernández-Ros, N; Huerta, A; Landecho, MF; Lucena, JF; Morales, MI; Rosado, IA | 1 |
| Agabiti Rosei, C; Agabiti Rosei, E; Bertacchini, F; Brami, V; Caletti, S; Coschignano, MA; De Ciuceis, C; Duse, S; Muiesan, ML; Paini, A; Petelca, A; Rizzoni, D; Rossini, C; Salvetti, M; Semeraro, F; Trapletti, V | 1 |
| Chen, Y; Jiang, G; Lv, Q; Yuan, J; Zhu, J; Zou, Y | 1 |
| Afonicheva, II; Beloborodova, AV; Melnik, MV | 1 |
| Cerbai, E; Mugelli, A | 1 |
| Chiarella, S; Coppolino, G; D'Onofrio, G; De Paola, L; Mileti, S; Nicotera, R; Panzino, A; Panzino, MT; Pinciaroli, AR; Placida, G | 1 |
| Castiglioni, P; Faini, A; Omboni, S; Parati, G | 1 |
| Caglayan, MG; Dogan-Topal, B; Karadurmus, L; Ozkan, SA; Shah, A; Shahzad, S; Taskin Tok, T; Uslu, B | 1 |
| Dienes, L; Finta, E; Kun, E; Simonyi, G | 1 |
| Mancia, G; Tsioufis, K | 1 |
| Balthazar Nardotto, GH; Barbosa Coelho, E; Dantas, M; Hanauer Schaab, E; Lanchote, VL; Marques Pereira, MP; Paiva, CE | 1 |
| Alekseev, AV; Khotko, AI; Khotko, DN; Popkov, VM; Tarasenko, AI; Zakharova, NB | 1 |
| Choi, KS; Hoon, H; Kim, IY; Kim, J; Lee, AR; Lee, DM; Seo, MJ; Yoon, MJ | 1 |
| Chiorcea-Paquim, AM; Fernandes, IG; Oliveira-Brett, AM | 1 |
| Abdessayed, N; Anoun, J; Ben Salem, C; Ben-Sayed, N; Fathallah, N; Ouni, B; Slim, R | 1 |
| Ding, L; Jiang, P; Li, L; Liu, S; Lu, W; Xu, X; Yang, C; Zhou, P | 1 |
| Arazzi, M; Colucci, M; Esposito, C; Esposito, V; Pasquinucci, E; Sileno, G | 1 |
| Ganesan, K; Panneerpandian, P; Rao, DB | 1 |
| Abohashrh, M; Ahmad, I; Alam, MM; Baig, MH; Dong, JJ; Sharma, T | 1 |
| Benetton, M; Bisio, V; Borella, G; Borile, G; Bresolin, S; Buldini, B; Cairo, S; Campodoni, E; Cani, A; Da Ros, A; Leszl, A; Locatelli, F; Marchetti, A; Michielotto, B; Montesi, M; Montini, B; Pigazzi, M; Porcù, E; Sandri, M; Tregnago, C | 1 |
| Eid, M; El-Masry, AA; El-Wasseef, DR; Shehata, IA; Zeid, AM | 1 |
| Ferrer, F; Figueiredo, CR; Gonçalves, H | 1 |
| Franczyk, B; Fularski, P; Hajdys, J; Leszto, K; Majchrowicz, G; Młynarska, E; Rysz, J; Stabrawa, M | 1 |
| Kvachakhiya, LL; Shormanov, VK | 1 |
35 review(s) available for lercanidipine and dihydropyridines
| Article | Year |
|---|---|
The pharmacological properties of lipophilic calcium antagonists.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Humans; Vasodilator Agents | 1998 |
Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cell Membrane; Cholesterol; Dihydropyridines; Half-Life; Humans; Models, Molecular | 1998 |
Clinical advantages of lipophilic dihydropyridines.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Middle Aged; Randomized Controlled Trials as Topic; Tachycardia | 1998 |
Lipophilic calcium antagonists in antiatherosclerotic therapy.
Topics: Arteriosclerosis; Calcium Channel Blockers; Cardiovascular System; Cell Division; Cell Movement; Dihydropyridines; Endothelium; Humans; Lipid Metabolism; Macrophages; Muscle, Smooth; Myocardium | 2000 |
Lercanidipine: a review of its use in hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Dihydropyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Hypertension | 2000 |
Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
Topics: Animals; Calcium Channel Blockers; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Interactions; Humans; Pharmaceutical Preparations | 2002 |
Lercanidipine : a review of its efficacy in the management of hypertension.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Drug Interactions; Humans; Hypertension | 2003 |
[Lercanidipine, a third generation calcium antagonist. Which advantages?].
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Dihydropyridines; Humans; Hypertension; Severity of Illness Index; Treatment Outcome | 2006 |
Hypertension, possible vascular protection and lercanidipine.
Topics: Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Edema; Humans; Hypertension; Randomized Controlled Trials as Topic | 2006 |
Fixed-dose combination lercanidipine/enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension | 2007 |
Lercanidipine in hypertension.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Severity of Illness Index; Treatment Outcome | 2005 |
Lercanidipine in the treatment of hypertension.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Humans; Hypertension | 2007 |
Fixed-dose lercanidipine/enalapril for hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Drug Interactions; Enalapril; Humans; Hypertension | 2008 |
Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension; Treatment Outcome | 2008 |
Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension; Medication Adherence | 2009 |
Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Medication Adherence; Proteinuria; Treatment Outcome | 2008 |
The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension | 2009 |
Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension | 2009 |
Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Edema; Humans; Hypertension; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Evidence-Based Medicine; Humans; Hypertension; Renin-Angiotensin System; Treatment Outcome | 2010 |
[Lerkanidipin: evolution of dihydropyridine calcium antagonists continues].
Topics: Age Factors; Aged; Atherosclerosis; Blood Pressure; Calcium Channel Blockers; Carotid Intima-Media Thickness; Dihydropyridines; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Pharmacovigilance; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Lercanidipine in the treatment of arterial hypertension].
Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Treatment Outcome | 2012 |
[The place of lercanidipine in the treatment of cardiovascular diseases].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Humans | 2013 |
[Clinical cfficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Medication Therapy Management; Outcome Assessment, Health Care; Protective Agents; Treatment Outcome | 2013 |
Renal protection with calcium antagonists: the role of lercanidipine.
Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; PubMed | 2013 |
[Treatment of arteril hypertension in patients with chronic kidney disease: a fixed combination of lercanidipine and enalapril].
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Combinations; Enalapril; Glomerular Filtration Rate; Humans; Hypertension; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
[Third generation calcium antagonist lercanidipine: the evidence base for clinical decision].
Topics: Calcium Channel Blockers; Dihydropyridines; Evidence-Based Medicine; Humans; Hypertension | 2014 |
[Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review)].
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Metabolic Diseases; Risk Factors; Treatment Outcome | 2015 |
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.
Topics: Amlodipine; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cattle; Dihydropyridines; Epithelial Cells; Humans; Hydrogen; Lipoproteins, LDL; Mice; Microsomes; Mitochondria; Niacinamide; Nifedipine; Nitrobenzenes; Oxidants; Oxidative Stress; Piperazines | 2016 |
Fixed-dose lercanidipine and enalapril in field practice: a meta-analysis.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Drug Therapy, Combination; Enalapril; Essential Hypertension; Female; Humans; Hypertension; Male; Middle Aged; Outcome Assessment, Health Care | 2016 |
Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension; Male; Middle Aged | 2016 |
Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Evidence-Based Medicine; Humans; Hypertension; Patient Satisfaction; Treatment Outcome | 2016 |
Lercanidipine-induced chylous ascites: Case report and literature review.
Topics: Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Chylous Ascites; Dihydropyridines; Female; Humans; Hypertension | 2017 |
[THE ROLE PLEIOTROPIC EFFECTS OF CALCIUM CHANNEL BLOCKER LERCANIDIPINE IN PERIOPERATIVE THERAPY OF ARTERIAL HYPERTENSION.]
Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Perioperative Care; Vascular Resistance | 2016 |
New Insights into the Nephroprotective Potential of Lercanidipine.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Renal Insufficiency, Chronic | 2023 |
61 trial(s) available for lercanidipine and dihydropyridines
| Article | Year |
|---|---|
Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Humans; Hypertension; Male; Middle Aged | 1998 |
Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Dihydropyridines; Female; Humans; Hypertension; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Retinal Artery; Treatment Outcome; Ultrasonography; Vascular Diseases | 2000 |
Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diastole; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Systole; Treatment Outcome | 2000 |
Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Enalapril; Female; Glycated Hemoglobin; Humans; Hypertension; Male; Metoprolol; Middle Aged; Regression Analysis; Vascular Resistance | 2001 |
Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Tolerance; Female; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Patient Dropouts; Prospective Studies | 2002 |
Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Area Under Curve; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Single-Blind Method | 2002 |
A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Severity of Illness Index; Tablets | 2002 |
Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Antioxidants; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydropyridines; Female; Humans; Hypertension; Lipoproteins, LDL; Losartan; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Single-Blind Method | 2002 |
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypertension; Male; Peripheral Vascular Diseases; Treatment Outcome | 2002 |
Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.
Topics: Antihypertensive Agents; Baroreflex; Blood Pressure; Dihydropyridines; Double-Blind Method; Felodipine; Heart Rate; Humans; Hypertension; Male; Middle Aged; Muscle, Skeletal; Norepinephrine; Sympathetic Nervous System; Time Factors | 2003 |
Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension.
Topics: Antioxidants; Ascorbic Acid; Calcium Channel Blockers; Dihydropyridines; Endothelium, Vascular; Female; Forearm; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Regional Blood Flow; Vasodilation | 2003 |
Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Volume; Calcium Channel Blockers; Diastole; Dihydropyridines; Drug Evaluation; Edema; Female; Heart Rate; Humans; Hypertension; Leg; Middle Aged; Norway; Postmenopause; Statistics as Topic; Systole; Time Factors; Treatment Outcome; Women's Health | 2003 |
Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Edema; Endpoint Determination; Female; Flushing; Headache; Heart Rate; Humans; Hypertension; Male; Middle Aged; Patient Dropouts | 2003 |
[Evaluation of lercanidipine in the general practice setting].
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Cholesterol; Diabetes Complications; Dihydropyridines; Family Practice; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Obesity; Treatment Outcome; Uric Acid | 2003 |
[Evaluation of psychosomatic symptomatology in hypertensive patients treated with lercanidipine (LERCAPSICO study)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Anxiety; Blood Glucose; Calcium Channel Blockers; Calcium Channels, L-Type; Cholesterol; Diabetes Complications; Diabetes Mellitus; Dihydropyridines; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Psychophysiologic Disorders; Treatment Outcome | 2003 |
Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension.
Topics: Adult; Aged; Calcium Channel Blockers; Dihydropyridines; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Nifedipine; Norepinephrine | 2003 |
Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Edema; Humans; Hypertension; Laser-Doppler Flowmetry; Leg; Male; Middle Aged; Skin; Treatment Outcome; Vasoconstriction | 2003 |
Lercanidipine vs lacidipine in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Supine Position; Treatment Outcome | 2003 |
Biological variability of albumin excretion rate and albumin-to-creatinine ratio in hypertensive type 2 diabetic patients.
Topics: Albuminuria; Calcium Channel Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Humans; Hypertension; Protein Denaturation; Sensitivity and Specificity; Serum Albumin; Temperature | 2003 |
[Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study].
Topics: Age Factors; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Edema; Female; Humans; Hypertension; Leg; Male; Middle Aged; Treatment Outcome | 2004 |
[Lercanidipine in diabetic patients with renal failure].
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Edema; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria; Treatment Outcome | 2004 |
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Treatment Outcome | 2004 |
Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Single-Blind Method | 2006 |
Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Female; Humans; Hypertension; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Oxidative Stress; Single-Blind Method; Tissue Inhibitor of Metalloproteinase-1 | 2006 |
Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters.
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Losartan; Male; Middle Aged; Plasminogen Activator Inhibitor 1 | 2006 |
Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cognition; Dihydropyridines; Doxazosin; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Psychiatric Status Rating Scales; Psychomotor Performance; Spain; Time Factors; Treatment Outcome | 2006 |
Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes.
Topics: Blood Vessels; Calcium Channel Blockers; Case-Control Studies; Dihydropyridines; Diuretics; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy; Male; Middle Aged; Vascular Resistance | 2006 |
Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM.
Topics: Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diastole; Dihydropyridines; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Placebos; Systole; Time Factors | 2007 |
Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Pressure; Dihydropyridines; Family Practice; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Sexual Dysfunction, Physiological; Sleep Wake Disorders | 2007 |
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Diuretics; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Sex Factors | 2007 |
High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cross-Sectional Studies; Dihydropyridines; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Nifedipine | 2008 |
Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cross-Sectional Studies; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Logistic Models; Male; Middle Aged; Nifedipine; Primary Health Care; Spain; Vasodilation | 2008 |
The combined effect of calcium channel blocker Lercanidipine and antioxidants on low-grade systemic inflammation parameters in essential hypertension patients.
Topics: Adult; Antioxidants; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Inflammation; Male; Middle Aged | 2008 |
Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Calcium Channel Blockers; Chromatography, Liquid; Cross-Over Studies; Dihydropyridines; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Statistics, Nonparametric; Stereoisomerism; Tandem Mass Spectrometry; Young Adult | 2009 |
Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Arteries; Atenolol; Bendroflumethiazide; Blood Pressure Determination; Dihydropyridines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Elasticity; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Perindopril; Probability; Regression Analysis; Risk Assessment; Systole; Treatment Outcome | 2009 |
Superior palatability of crushed lercanidipine compared with amlodipine among children.
Topics: Administration, Oral; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Dihydropyridines; Female; Humans; Kidney Diseases; Male; Patient Compliance; Patient Satisfaction; Single-Blind Method; Smell; Statistics as Topic; Taste | 2010 |
Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Dihydropyridines; Drug Combinations; Enalapril; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prospective Studies | 2010 |
Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Body Composition; Body Water; Dihydropyridines; Edema; Electric Impedance; Extracellular Fluid; Female; Humans; Hypertension; Intracellular Fluid; Male; Middle Aged; Outpatients; Prospective Studies; Thailand; Treatment Outcome | 2010 |
Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cholesterol; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Middle Aged; Triglycerides | 2012 |
Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure.
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Drug Combinations; Enalapril; Female; Follow-Up Studies; Germany; Humans; Male; Prospective Studies; Surveys and Questionnaires; Treatment Outcome | 2011 |
Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake.
Topics: Area Under Curve; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Cross-Over Studies; Data Interpretation, Statistical; Dietary Carbohydrates; Dietary Fats; Dihydropyridines; Drug Administration Schedule; Drug Labeling; Eating; Fasting; Female; Food-Drug Interactions; Humans; Male; Pilot Projects; Stereoisomerism; Therapeutic Equivalency; Time Factors | 2012 |
Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Single-Blind Method | 2013 |
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; CD40 Ligand; Dihydropyridines; Double-Blind Method; Drug Combinations; Enalapril; Female; Humans; Hypertension; Lipids; Male; Middle Aged; Peroxidase; Risk Factors | 2014 |
Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Humans; Hypertension; Italy; Lipids; Male; Risk Factors; Survival Rate; Treatment Outcome | 2014 |
Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Combinations; Enalapril; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged | 2014 |
Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Dihydropyridines; Drug Therapy, Combination; Essential Hypertension; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Perindopril; Treatment Outcome | 2015 |
Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study.
Topics: Adult; Antihypertensive Agents; Dihydropyridines; Drug Combinations; Enalapril; Female; Heart Rate; Humans; Hypertension; Lebanon; Lipids; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2015 |
Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Felodipine; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Treatment Outcome; Young Adult | 2015 |
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Brain Ischemia; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Stroke; Treatment Outcome | 2015 |
Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Italy; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Stiffness | 2017 |
Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Headache; Humans; Hypertension; Male; Middle Aged; Treatment Outcome; Valsartan; Young Adult | 2015 |
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Nifedipine; Treatment Outcome | 2015 |
Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Databases, Factual; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension; Intention to Treat Analysis; Male; Middle Aged; Office Visits; Self Care | 2016 |
Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Felodipine; Female; Heart Rate; Humans; Hypertension; Insulin Resistance; Male; Metabolome; Middle Aged; Norepinephrine; Obesity; Random Allocation; Sympathetic Nervous System | 2016 |
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypertension; Italy; Losartan; Male; Middle Aged; Nifedipine; Oxidative Stress; Time Factors; Treatment Outcome | 2016 |
A rapid and sensitive LC-MS/MS method for determination of lercanidipine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers.
Topics: Chromatography, Liquid; Cross-Over Studies; Dihydropyridines; Healthy Volunteers; Humans; Male; Plasma; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency | 2016 |
Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Delayed-Action Preparations; Dihydropyridines; Felodipine; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Treatment Outcome | 2016 |
Lercanidipine effect on circulating CD34+ progenitor cells in elderly patients: a randomized study.
Topics: Aged; Antigens, CD34; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Female; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hypertension; Male; Middle Aged | 2016 |
Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Prospective Studies | 2016 |
Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Kidney; Male; Middle Aged; Sympathetic Nervous System; Vascular Stiffness | 2016 |
Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Carvedilol; Case-Control Studies; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Interactions; Female; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Stereoisomerism | 2020 |
133 other study(ies) available for lercanidipine and dihydropyridines
| Article | Year |
|---|---|
Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Catheterization; Dihydropyridines; Dogs; Heart Rate; Hypertension; Hypertension, Renal; Injections, Intravenous; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley | 1996 |
Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Topics: Adrenergic alpha-Agonists; Animals; Binding, Competitive; Brain; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Dihydropyridines; Guinea Pigs; In Vitro Techniques; Male; Muscle Contraction; Muscle, Skeletal; Muscle, Smooth, Vascular; Myocardial Contraction; Myocardium; Norepinephrine; Potassium; Rabbits; Rats; Rats, Sprague-Dawley | 1996 |
Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs.
Topics: Anesthesia; Animals; Calcium Channel Blockers; Dihydropyridines; Dogs; Dose-Response Relationship, Drug; Hemodynamics; Injections, Intravenous; Male; Nitrendipine; Time Factors | 1996 |
Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes.
Topics: Animals; Aorta; Brain; Calcium; Calcium Channel Blockers; Calcium Channels; Cell Division; Cell Movement; Cells, Cultured; Dihydropyridines; Dose-Response Relationship, Drug; Humans; Male; Muscle, Smooth, Vascular; Nitrendipine; Rats; Rats, Sprague-Dawley; Stereoisomerism | 1996 |
The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved?
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Brain; Calcium Channel Blockers; Cell Division; Dihydropyridines; In Vitro Techniques; Male; Membranes; Muscle, Smooth, Vascular; Nitrendipine; Rats; Rats, Sprague-Dawley; Stereoisomerism | 1998 |
Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits.
Topics: Animals; Arteries; Arteriosclerosis; Calcium Channel Blockers; Cholesterol, Dietary; Dihydropyridines; Disease Models, Animal; Hypercholesterolemia; Hyperplasia; Macrophages; Male; Rabbits | 1998 |
Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
Topics: Animals; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Myocardial Contraction; Rabbits; Vasodilation | 1999 |
[Pharma-clinics. Drug of the month. Lercanidipine (Zanidip)].
Topics: Antihypertensive Agents; Blood Pressure; Dihydropyridines; Half-Life; Humans; Hypertension | 1999 |
Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats.
Topics: Albuminuria; Animals; Arterioles; Calcium; Calcium Channel Blockers; Dihydropyridines; Hydralazine; Hypertension, Renal; Juxtaglomerular Apparatus; Male; Nicardipine; Nitrobenzenes; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Vasodilator Agents | 2000 |
Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hydralazine; Kidney; Kidney Cortex; Kidney Glomerulus; Kidney Tubules; Male; Nicardipine; Nitrobenzenes; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasodilator Agents | 2000 |
Electrophysiologic effects of lercanidipine on repolarizing potassium currents.
Topics: Action Potentials; Animals; Butylamines; Calcium Channel Blockers; Dihydropyridines; Diphenhydramine; Electric Stimulation; Guinea Pigs; Heart; Humans; Potassium Channels; Prenylamine; Rats; Species Specificity; Structure-Activity Relationship | 2000 |
[Modern calcium channel blockade. Lowering blood pressure with added benefits].
Topics: Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension | 2001 |
Influence of treatment with Ca(2+) antagonists on cerebral vasculature of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain; Calcium Channel Blockers; Cerebrovascular Circulation; Dihydropyridines; Hydralazine; Hypertension; Male; Nimodipine; Nitrobenzenes; Piperazines; Rats; Rats, Inbred SHR; Rats, Wistar | 2001 |
[Hypertension in type 2 diabetic patients. Calcium antagonist supports the left heart].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Treatment Outcome | 2001 |
Oxygen-free radical decrease in hypertensive patients treated with lercanidipine.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Electrocardiography; Female; Free Radicals; Heart Rate; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Oxygen; Time Factors | 2001 |
Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Brain; Brain Injuries; Calcium Channel Blockers; Dihydropyridines; Frontal Lobe; Hippocampus; Hypertension; Male; Nimodipine; Nitrobenzenes; Occipital Lobe; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2001 |
[New calcium antagonist. Therapy of hypertension becomes more tolerable].
Topics: Calcium Channel Blockers; Dihydropyridines; Drug Approval; Germany; Humans; Hypertension | 2001 |
Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats.
Topics: Acetylcholine; Animals; Antioxidants; Aorta, Thoracic; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dihydropyridines; Female; Iloprost; In Vitro Techniques; Male; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Norepinephrine; Rats; Sex Factors; Superoxide Dismutase; Vasoconstriction; Vasodilator Agents | 2001 |
Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hydralazine; Kidney; Male; Nicardipine; Nitrobenzenes; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Tunica Media; Vasodilator Agents | 2002 |
Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension.
Topics: Animals; Ankle; Calcium Channel Blockers; Dihydropyridines; Edema; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney | 2002 |
A selective HPLC method for determination of lercanidipine in tablets.
Topics: Calcium Channel Blockers; Calibration; Chromatography, High Pressure Liquid; Dihydropyridines; Electrochemistry; Hot Temperature; Hydrolysis; Indicators and Reagents; Oxidation-Reduction; Photolysis; Solutions; Spectrophotometry, Ultraviolet; Tablets | 2003 |
Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters.
Topics: Acetylcholine; Animals; Calcium Channel Blockers; Capillaries; Cardiomyopathies; Cardiotonic Agents; Cricetinae; Dihydropyridines; Female; Heart Failure; Male; Mesocricetus; Myocardium; Nitroprusside; Vasodilator Agents; Ventricular Remodeling | 2003 |
[Depot calcium antagonist. General practice study confirms good tolerance].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Delayed-Action Preparations; Dihydropyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypertension | 2003 |
Emerging data on calcium-channel blockers: the COHORT study.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2003 |
Antioxidant activity of different dihydropyridines.
Topics: Amlodipine; Animals; Antioxidants; Cattle; Cells, Cultured; Dihydropyridines; Endothelium, Vascular; Fluoresceins; Humans; Lipoproteins, LDL; Molecular Structure; Nifedipine; Nimodipine; Reactive Oxygen Species | 2003 |
Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium Channel Blockers; Coronary Vessels; Diabetes Mellitus, Type 2; Dihydropyridines; Heart; Hypertension; Male; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rats, Inbred WKY | 2003 |
[Therapy of hypertension is mostly combination therapy. Calcium antagonists are ideal partners].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension | 2003 |
Antioxidant effect of lercanidipine.
Topics: Antioxidants; Dihydropyridines; Ferric Compounds; Humans; Oxidation-Reduction | 2003 |
[Most hypertensive patients need drug combination treatment. "First line therapy is in second place"].
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Nitrendipine | 2003 |
Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2003 |
Extractive spectrophotometric methods for determination of lercanidipine.
Topics: Algorithms; Bromcresol Green; Bromthymol Blue; Calcium Channel Blockers; Dihydropyridines; Indicators and Reagents; Pharmaceutical Solutions; Spectrophotometry, Ultraviolet; Tablets | 2003 |
Selective and rapid liquid chromatography-mass spectrometry method for the determination of lercanidipine in human plasma.
Topics: Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2004 |
Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.
Topics: Animals; Calcium Channels, L-Type; CHO Cells; Cricetinae; Dihydropyridines; Dose-Response Relationship, Drug; Endothelium, Vascular; Protein Isoforms; Rabbits | 2004 |
In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages.
Topics: Animals; Calcium Channel Blockers; Cells, Cultured; Cholesterol; Cholesterol Esters; Dihydropyridines; Electrophoresis, Polyacrylamide Gel; Humans; In Vitro Techniques; Macrophages, Peritoneal; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Monocytes; Species Specificity | 2004 |
Enantioselective pharmacokinetics of lercanidipine in healthy volunteers.
Topics: Area Under Curve; Calcium Channel Blockers; Dihydropyridines; Humans | 2004 |
[Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Contraindications; Dihydropyridines; Drug Interactions; Humans; Hypertension | 2005 |
Lercanidipine in patients with chronic renal failure: the ZAFRA study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Treatment Outcome | 2005 |
[Lowering blood pressure with new calcium antagonists. High benefit by innovative mechanism of action].
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Administration Schedule; Endothelium, Vascular; Humans; Hypertension; Patient Compliance; Treatment Outcome | 2005 |
[Also for problem cases; successful first line therapy].
Topics: Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Treatment Outcome | 2005 |
Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats.
Topics: Animals; Avoidance Learning; Brain; Calcium Channel Blockers; Cerebral Ventricles; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Drug Combinations; Indans; Injections; Male; Maze Learning; Memory; Memory Disorders; Piperidines; Rats; Rats, Sprague-Dawley; Streptozocin | 2005 |
Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats.
Topics: Angina Pectoris; Animals; Dihydropyridines; Disease Models, Animal; Male; Methacholine Chloride; Rats; Rats, Sprague-Dawley; Vasodilator Agents; Vasopressins | 2005 |
[What chance is there that the patient will be treated!].
Topics: Antihypertensive Agents; Chylous Ascites; Dihydropyridines; Humans; Hypertension; Male; Middle Aged | 2005 |
Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue.
Topics: Adolescent; Adult; Aged; Amlodipine; Binding, Competitive; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Female; Humans; In Vitro Techniques; Male; Mammary Arteries; Middle Aged; Myocardial Contraction; Nifedipine; Protein Binding; Stimulation, Chemical; Vasodilation | 2005 |
Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Pilot Projects; Prospective Studies | 2005 |
Investigation on the photochemical stability of lercanidipine and its determination in tablets by HPLC-UV and LC-ESI-MS/MS.
Topics: Calcium Channel Blockers; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dihydropyridines; Ethanol; Kinetics; Light; Mass Spectrometry; Models, Chemical; Photochemistry; Solvents; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Tablets | 2006 |
Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
Topics: Albumins; Amidohydrolases; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Arginine; Calcium Channel Blockers; Dihydropyridines; Gene Expression Regulation, Enzymologic; Hypertension; Kidney; Rats; Rats, Sprague-Dawley; Renin | 2006 |
Cloudy dialysate due to lercanidipine.
Topics: Adult; Calcium Channel Blockers; Dialysis Solutions; Dihydropyridines; Female; Humans; Male; Middle Aged; Peritoneal Dialysis; Triglycerides | 2006 |
[Hypertensive patients can benefit from a new generation of calcium channel blockers. Lercanidipine: effective with few side effects].
Topics: Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension | 2006 |
Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma.
Topics: Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2006 |
[Antihypertensive agents used as first line agents: beta-blockers under pressure].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Dihydropyridines; Diuretics; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Spironolactone; Treatment Outcome | 2006 |
Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study.
Topics: Aged; Analysis of Variance; Antihypertensive Agents; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Risk Factors; Treatment Outcome | 2006 |
[The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients].
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; Inflammation; Middle Aged; Neutrophils | 2006 |
Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Hypertension; Kidney; Male; Rats; Renal Artery; Renal Circulation | 2007 |
Development and evaluation of buccoadhesive controlled release tablets of lercanidipine.
Topics: Adhesiveness; Administration, Buccal; Animals; Cheek; Delayed-Action Preparations; Diffusion; Dihydropyridines; Drug Compounding; Drug Evaluation, Preclinical; In Vitro Techniques; Materials Testing; Swine; Tissue Adhesives | 2008 |
Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Enzyme Precursors; Gelatinases; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Oxidative Stress; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Thiobarbituric Acid Reactive Substances; Vasodilation | 2008 |
Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.
Topics: Alloxan; Animals; Antihypertensive Agents; Antioxidants; Aorta, Thoracic; Blood Pressure; Diabetes Mellitus, Experimental; Dihydropyridines; Enzyme Precursors; Fluorometry; Gelatinases; Gene Expression Regulation, Enzymologic; Male; Matrix Metalloproteinase 2; Oxidative Stress; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiobarbituric Acid Reactive Substances; Tissue Inhibitor of Metalloproteinase-2 | 2008 |
Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling.
Topics: Animals; Becaplermin; Calcium Channel Blockers; Cell Movement; Cell Proliferation; Dihydropyridines; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Male; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Platelet-Derived Growth Factor; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-sis; ras Proteins; Rats; Rats, Wistar; Reactive Oxygen Species; STAT3 Transcription Factor; Tunica Intima | 2009 |
Calcium channel blocker-induced chylous ascites in peritoneal dialysis.
Topics: Adult; Calcium Channel Blockers; Chylous Ascites; Dihydropyridines; Female; Humans; Peritoneal Dialysis | 2009 |
Efficacy and tolerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups.
Topics: Antihypertensive Agents; Asia; Calcium Channel Blockers; Confidence Intervals; Diastole; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Singapore; Systole | 2009 |
Formulation and in vitro evaluation of buoyant controlled release lercanidipine lipospheres.
Topics: Calcium Channel Blockers; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dihydropyridines; Drug Evaluation, Preclinical; In Vitro Techniques; Microspheres; Particle Size; X-Ray Diffraction | 2009 |
Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients.
Topics: Adrenergic beta-Antagonists; Adult; Calcium Channel Blockers; Carbazoles; Carvedilol; Dihydropyridines; Female; Humans; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritoneum; Propanolamines; Ultrafiltration | 2009 |
Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Proteinuria; Statistics, Nonparametric; Treatment Outcome | 2010 |
Calcium channel blocker.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Data Interpretation, Statistical; Dihydropyridines; Edema; Humans; Hypertension; Meta-Analysis as Topic; Risk Assessment; Treatment Outcome | 2010 |
Hypertension may affect tooth-supporting alveolar bone quality: a study in rats.
Topics: Acid Phosphatase; Alveolar Bone Loss; Alveolar Process; Animals; Antihypertensive Agents; Biomarkers; Bone Density; Dihydropyridines; Hypertension; Immunohistochemistry; Isoenzymes; Male; Molar; Osteoprotegerin; RANK Ligand; Rats; Rats, Inbred SHR; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Tooth Root | 2010 |
[First episode of atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dihydropyridines; Electric Countershock; Electrocardiography; Humans; Male; Treatment Outcome | 2010 |
Determination of pK(a) values of some antihypertensive drugs by liquid chromatography and simultaneous assay of lercanidipine and enalapril in their binary mixtures.
Topics: Antihypertensive Agents; Chromatography, Liquid; Dihydropyridines; Enalapril; Limit of Detection | 2010 |
Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.
Topics: Adult; Aged; Calcium Channel Blockers; Dialysis Solutions; Dihydropyridines; Female; Humans; Male; Middle Aged; Nephelometry and Turbidimetry; Peritoneal Dialysis, Continuous Ambulatory; Statistics, Nonparametric | 2010 |
Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Drug Synergism; Heart Rate; Hypertension; Kinetics; Male; Random Allocation; Rats; Rats, Inbred SHR; Statistics as Topic; Telmisartan | 2010 |
Management of lercanidipine overdose with hyperinsulinaemic euglycaemia therapy: case report.
Topics: Antidotes; Calcium Channel Blockers; Dihydropyridines; Drug Overdose; Glucagon; Glucose; Glucose Clamp Technique; Humans; Hypotension; Insulin; Male; Middle Aged | 2011 |
Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.
Topics: Animals; Antihypertensive Agents; Calcium Channel Blockers; Cell Death; Dihydropyridines; Hippocampus; Ischemia; Neurons; Pyramidal Cells; Rats; Rats, Inbred SHR; Stroke | 2011 |
Lercanidipine-associated nocturia.
Topics: Antihypertensive Agents; Dihydropyridines; Humans; Hypertension; Male; Middle Aged; Nocturia | 2011 |
Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system.
Topics: Administration, Oral; Biological Availability; Calcium Channel Blockers; Capsules; Chemistry, Pharmaceutical; Dihydropyridines; Drug Compounding; Drug Delivery Systems; Drug Stability; Emulsifying Agents; Excipients; Microscopy, Electron, Transmission; Nanoparticles; Oils; Particle Size; Solubility; Viscosity | 2011 |
[Fixed combination enalapril/lercanidipine in routine treatment: consistent RR reduction with kidney protection].
Topics: Antihypertensive Agents; Dihydropyridines; Drug Combinations; Electrocardiography; Enalapril; Humans; Hypertension; Kidney Function Tests; Proteinuria | 2011 |
Assay of lercanidipine hydrochloride in dosage forms using nucleophilic substitution reaction.
Topics: Chemistry, Pharmaceutical; Dihydropyridines; Dosage Forms; Spectrophotometry, Ultraviolet | 2011 |
[ACE inhibitor and calcium antagonist in fixed combination: effective protection for hypertensive patients at risk].
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Combined Modality Therapy; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hypertension; Physical Fitness; Stroke | 2012 |
Polymorphism of the methylenetetrahydrofolate reductase gene C677T and its influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment.
Topics: Adult; Ankle Brachial Index; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Genotype; Humans; Hypertension; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Phenotype; Polymorphism, Genetic; Time Factors | 2012 |
Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Chromatography, High Pressure Liquid; Dihydropyridines; Dogs; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Formulation and evaluation of bilayered gastroretentable mucoadhesive patch for stomach-specific drug delivery.
Topics: Adhesiveness; Animals; Antihypertensive Agents; Dihydropyridines; Drug Delivery Systems; Gastric Mucosa; Hypromellose Derivatives; Male; Methylcellulose; Polymers; Rabbits; Rats; Solubility; Tensile Strength | 2013 |
Effects of lercanidipine on bone density and bone repair in spontaneously hypertensive rats.
Topics: Acid Phosphatase; Animals; Antihypertensive Agents; Biomarkers; Bone Density; Bone Diseases; Bone Regeneration; Calcium Channel Blockers; Dihydropyridines; Hypertension; Image Processing, Computer-Assisted; Isoenzymes; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Tibia; Wound Healing | 2013 |
Lercanidipine and labedipinedilol--A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities.
Topics: Animals; Anisoles; Anti-Inflammatory Agents; Dihydropyridines; HMGB1 Protein; Inflammation; Interferon-gamma; Lipopolysaccharides; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Rats; Tissue Inhibitor of Metalloproteinase-1 | 2013 |
Transdermal delivery of lercanidipine hydrochloride: effect of chemical enhancers and ultrasound.
Topics: Adjuvants, Pharmaceutic; Administration, Cutaneous; Animals; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Dimethylformamide; Ethanol; In Vitro Techniques; Mice; Permeability; Polysorbates; Skin Absorption; Solubility; Sonication | 2013 |
Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients.
Topics: Adult; Aged; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Inflammation Mediators; Insulin Resistance; Male; Middle Aged; Prospective Studies; Young Adult | 2013 |
[Consistence of the radial artery as a conduit used in aortocoronary bypass surgery, a possibility of preventing shunt spasm].
Topics: Aged; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Stenosis; Dihydropyridines; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Monitoring, Intraoperative; Nitric Oxide; Predictive Value of Tests; Preoperative Care; Radial Artery; Ultrasonography; Vasodilation | 2012 |
Calcium Antagonists Use and Its Association with Lower Urinary Tract Symptoms: A Cross-Sectional Study.
Topics: Aged; Calcium Channel Blockers; Cross-Sectional Studies; Dihydropyridines; Felodipine; Female; Humans; Hypertension; Interviews as Topic; Logistic Models; Lower Urinary Tract Symptoms; Male; Middle Aged; Odds Ratio; Severity of Illness Index; Surveys and Questionnaires | 2013 |
CXCR7 upregulation is required for early endothelial progenitor cell-mediated endothelial repair in patients with hypertension.
Topics: Animals; Antihypertensive Agents; Apoptosis; Carotid Artery Injuries; Caspase 3; Cell Adhesion; Cells, Cultured; Dihydropyridines; Endothelial Cells; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Receptors, CXCR; Transfection; Up-Regulation | 2014 |
Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioles; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Enalapril; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Kidney; Laser-Doppler Flowmetry; Male; Middle Aged; Oxidative Stress; Ultrasonography | 2014 |
Anal fissure nanocarrier of lercanidipine for enhanced transdermal delivery: formulation optimization, ex vivo and in vivo assessment.
Topics: Administration, Cutaneous; Anal Canal; Animals; Calcium Channel Blockers; Chemistry, Pharmaceutical; Dihydropyridines; Drug Delivery Systems; Fissure in Ano; Gels; Male; Microscopy, Electron, Transmission; Muscle, Smooth; Particle Size; Rats; Rats, Wistar; Rectum; Refractometry; Skin; Skin Absorption; Viscosity | 2014 |
Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Topics: Administration, Oral; Animals; Blood Pressure; Calcium; Diffusion; Dihydropyridines; Drug Carriers; Drug Delivery Systems; Hypertension; Kinetics; Lipids; Male; Molecular Structure; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Surface Properties | 2014 |
Flow injection chemiluminescence determination of lercanidipine based on N-chlorosuccinimide-eosin Y post-chemiluminescence reaction.
Topics: Administration, Oral; Artifacts; Cetrimonium; Cetrimonium Compounds; Dihydropyridines; Eosine Yellowish-(YS); Flow Injection Analysis; Fluorescent Dyes; Humans; Kinetics; Limit of Detection; Luminescent Measurements; Sodium Hydroxide; Succinimides; Surface-Active Agents; Tablets | 2014 |
Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Enalapril; Essential Hypertension; Female; Glucose Transporter Type 4; Humans; Hypertension; Insulin; Lymphocytes; Male; Middle Aged; Monocytes; Nifedipine; Pilot Projects; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Olmesartan induced enterocolitis.
Topics: Aged; Amitriptyline; Anticholesteremic Agents; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Atenolol; Atorvastatin; Dihydropyridines; Enterocolitis; Female; Heptanoic Acids; Humans; Imidazoles; Pyrroles; Tetrazoles | 2014 |
Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Patient Safety; Portugal | 2014 |
Medical treatment of an adult with uncorrected isolated interrupted aorta resulted in no complications after 4 years of follow-up.
Topics: Angiography; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Aorta, Thoracic; Biphenyl Compounds; Blood Flow Velocity; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Irbesartan; Middle Aged; Multidetector Computed Tomography; Tetrazoles; Time Factors; Vascular Malformations | 2014 |
Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant.
Topics: Administration, Oral; Biological Availability; Dihydropyridines; Drug Compounding; Humans; Hypromellose Derivatives; Nanoparticles; Particle Size; Poloxamer; Polyethylene Glycols; Solubility; Vitamin E | 2015 |
Determination of the purity of pharmaceutical reference materials by 1H NMR using the standardless PULCON methodology.
Topics: Amantadine; Ambroxol; Calibration; Chromatography, High Pressure Liquid; Dihydropyridines; Diphosphonates; Drug Contamination; Ibandronic Acid; Models, Chemical; Pharmaceutical Preparations; Proton Magnetic Resonance Spectroscopy; Reference Standards; Reproducibility of Results; Technology, Pharmaceutical | 2014 |
Non-infectious cloudy peritoneal fluid secondary to lercanidipine.
Topics: Ascitic Fluid; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Middle Aged | 2014 |
Continuous venovenous hemodiafiltration along with charcoal hemoperfusion for the management of life-threatening lercanidipine and amlodipine overdose.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Charcoal; Dihydropyridines; Drug Overdose; Hemodiafiltration; Hemoperfusion; Humans; Male; Multiple Organ Failure; Shock; Time Factors; Treatment Outcome | 2014 |
Gingival overgrowth as secondary effect of calcium channel blockers administration. A case report.
Topics: Calcium Channel Blockers; Dental Prophylaxis; Denture, Partial; Dihydropyridines; Female; Gingival Overgrowth; Gingivectomy; Humans; Hypertension; Middle Aged | 2014 |
Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?
Topics: Adult; Aged; Angioplasty, Balloon; Antihypertensive Agents; Atherosclerosis; Blood Pressure Monitoring, Ambulatory; Cohort Studies; Creatinine; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Renal Artery Obstruction; Stents; Treatment Outcome | 2015 |
Lercanidipine in worldwide usage.
Topics: Antihypertensive Agents; China; Dihydropyridines; Humans; Hypertension; Lebanon; Vietnam | 2015 |
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dihydropyridines; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Perindopril; Propensity Score; Ramipril; Retrospective Studies; Risk Factors; Telmisartan; Tetrazoles | 2015 |
Gastroretentive pulsatile release tablets of lercanidipine HCl: development, statistical optimization, and in vitro and in vivo evaluation.
Topics: Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dihydropyridines; Gastric Mucosa; Male; Microscopy, Electron, Scanning; Polyethylene Glycols; Rabbits; Radiography; Reproducibility of Results; Spectroscopy, Fourier Transform Infrared; Statistics as Topic; Stomach; Tablets; Time Factors | 2014 |
[Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Proffie in Elderly Patients With Arterial Hypertension].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Humans; Hypertension; Male; Treatment Outcome | 2015 |
Calcium Channel Blockers--Benefits Upon Vascular Biology in Hypertensive Patients.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Vascular Stiffness | 2015 |
Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Topics: Adenine; Aged; Antihypertensive Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dihydropyridines; Drug Interactions; Humans; Lymphoma, Mantle-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Verapamil | 2016 |
Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation.
Topics: Administration, Oral; Animals; Calcium Channel Blockers; Dihydropyridines; In Vitro Techniques; Mouth Mucosa; Nanoparticles; Permeability; Solubility; Spectroscopy, Fourier Transform Infrared; Swine; X-Ray Diffraction | 2016 |
Effect of antihypertensive treatment with lercanidipine on endothelial progenitor cells and inflammation in patients with mild to moderate essential hypertension.
Topics: Antihypertensive Agents; Dihydropyridines; Endothelial Progenitor Cells; Essential Hypertension; Female; Humans; Hypertension; Inflammation; Male; Middle Aged; Risk Factors | 2016 |
A novel nanoproliposomes of lercanidipine: Development, in vitro and preclinical studies to support its effectiveness in hypertension therapy.
Topics: Animals; Antihypertensive Agents; Calorimetry, Differential Scanning; Dihydropyridines; Hypertension; In Vitro Techniques; Liposomes; Nanoparticles; Rabbits; Rats; Rats, Wistar; X-Ray Diffraction | 2016 |
Vascular effects of the lercanidipine/enalapril combination: clinical relevance.
Topics: Antihypertensive Agents; Blood Pressure; Blood Vessels; Dihydropyridines; Drug Therapy, Combination; Enalapril; Humans; Hypertension | 2016 |
Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats.
Topics: Animals; Blood Pressure; Brain Infarction; Caspase 3; Caspase 9; Cerebrovascular Circulation; Dihydropyridines; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 2; Motor Activity; Nervous System Diseases; Neuroprotective Agents; Rats; Rats, Wistar | 2017 |
Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Substitution; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Product Surveillance, Postmarketing; Prospective Studies; Time Factors; Treatment Outcome | 2017 |
Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Dihydropyridines; Felodipine; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Stroke; Taiwan; Young Adult | 2017 |
Comparison of lercanidipine plus hydrochlorothiazide vs. lercanidipine plus enalapril on micro and macrocirculation in patients with mild essential hypertension.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged | 2017 |
Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Calcineurin; Calcium Channel Blockers; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Cells, Cultured; Dihydropyridines; Gene Expression Regulation; Histone Deacetylases; Myocytes, Cardiac; Natriuretic Peptide, Brain; NFATC Transcription Factors; Rats; Signal Transduction | 2017 |
Lercanidipine and T-type calcium current.
Topics: Action Potentials; Animals; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Dihydropyridines; Guinea Pigs; Myocytes, Cardiac | 2018 |
[Possible role of Lercanidipine in Chiloperitoneum occurrence in CAPD: a case-report].
Topics: Calcium Channel Blockers; Chylous Ascites; Dihydropyridines; Female; Humans; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory | 2018 |
Effects on 24-hour blood pressure variability of ace-inhibition and calcium channel blockade as monotherapy or in combination.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium; Calcium Channel Blockers; Calcium Channels; Dihydropyridines; Enalapril; Female; Humans; Hypertension; Male; Middle Aged | 2018 |
Electrochemical, spectroscopic and molecular docking studies on the interaction of calcium channel blockers with dsDNA.
Topics: Animals; Binding Sites; Biosensing Techniques; Calcium Channel Blockers; Cattle; Dihydropyridines; DNA; Electrochemical Techniques; Intercalating Agents; Molecular Docking Simulation; Nifedipine; Nucleic Acid Conformation | 2019 |
[Infrequent systemic drug interaction: repeated syncope caused by combined treatment with timolol-containing eye drops and lercanidipine tablet].
Topics: Dihydropyridines; Drug Interactions; Humans; Ophthalmic Solutions; Syncope; Tablets; Timolol | 2019 |
Current perspective on the use of calcium channel blockers to treat hypertensive patients: the role of lercanidipine.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Practice Guidelines as Topic; Precision Medicine | 2019 |
[Nephroprotective effect of calcium channel blocker lercanidipine in treatment of patients with urolithiasis and urinary tract obstruction and monitoring of the serum cytokine profile].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Calcium Channel Blockers; Cytokines; Dihydropyridines; Glomerular Filtration Rate; Humans; Kidney; Nephrolithiasis; Neuroprotective Agents; Treatment Outcome; Urolithiasis | 2019 |
Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
Topics: Apoptosis; Bortezomib; Calcium; Cell Line, Tumor; Cell Survival; Dihydropyridines; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Ions; Mitochondria; Proteasome Inhibitors; Vacuoles | 2019 |
Topics: Animals; Dihydropyridines; Infarction, Middle Cerebral Artery; Ischemic Stroke; Magnetic Resonance Spectroscopy; Male; Rats; Rats, Wistar; Reperfusion Injury | 2020 |
Calcium channel blocker lercanidipine electrochemistry using a carbon black-modified glassy carbon electrode.
Topics: Boron; Calcium Channel Blockers; Dihydropyridines; Electrochemical Techniques; Electrodes; Electrons; Nanostructures; Oxidation-Reduction; Protons; Soot | 2020 |
Enalapril-lercanidipine combination induced leukocytoclastic vasculitis: A case report.
Topics: Dihydropyridines; Enalapril; Humans; Hypertension; Vasculitis, Leukocytoclastic, Cutaneous | 2021 |
T-type calcium channels blockers inhibit HSV-2 infection at the late stage of genome replication.
Topics: Animals; Antiviral Agents; Calcium Channel Blockers; Calcium Channels, T-Type; Calcium Signaling; Chlorocebus aethiops; Dihydropyridines; Gene Expression Regulation, Viral; HeLa Cells; Herpes Genitalis; Herpesvirus 2, Human; Host-Pathogen Interactions; Humans; Piperazines; Vero Cells; Virus Replication | 2021 |
Don't judge the book by its cover….
Topics: Chylous Ascites; Dihydropyridines; Humans; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Renal Insufficiency, Chronic | 2021 |
Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin.
Topics: Amlodipine; Antibiotics, Antineoplastic; Calcium Channel Blockers; Cell Line; Cell Survival; Dihydropyridines; Doxorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Stomach Neoplasms; Transcription, Genetic; Transcriptome; Transforming Growth Factor beta; YY1 Transcription Factor | 2021 |
Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
Topics: Antiviral Agents; Binding Sites; Computer Simulation; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Databases, Protein; Diarylquinolines; Dihydropyridines; Humans; Indoles; Leucine; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitrobenzenes; Nitrophenols; Organophosphorus Compounds; Piperazines; Proline; Protease Inhibitors; Pyrrolidinones; SARS-CoV-2 | 2021 |
Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia.
Topics: Calcium Channels, L-Type; Cell Proliferation; Dihydropyridines; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Neoplasm Proteins; Transcriptome; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Optimization and Validation of a Facile RP-HPLC Method for Determination of Betrixaban and Lercanidipine in Pharmaceutical and Biological Matrices.
Topics: Benzamides; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Limit of Detection; Pharmaceutical Preparations; Pyridines; Reproducibility of Results | 2021 |
Milky effluent associated to lercanidipine in a peritoneal dialysis European patient.
Topics: Dialysis Solutions; Dihydropyridines; Humans; Peritoneal Dialysis | 2022 |
[Lercanidipine distribution in warm-blooded animals].
Topics: Animals; Chromatography, High Pressure Liquid; Dihydropyridines; Rats; Rats, Wistar; Stomach; Water | 2023 |